Literature DB >> 8515055

Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins.

W H Alwan1, F M Record, P J Openshaw.   

Abstract

Mice sensitized to individual respiratory syncytial (RS) virus proteins show distinct patterns of immunity and pulmonary pathology when challenged with live virus. To explore the immune mechanisms responsible for the differences in postvaccination disease, BALB/c (H-2d) mice were primed by scarification with recombinant vaccinia viruses (rVV) expressing the major glycoprotein (G), fusion protein (F), phosphoprotein (P), nucleoprotein (N), or second matrix (22K) protein of RS virus. Ag-stimulated spleen cell cultures gave rise to CD3+TCR-alpha beta + T cell lines. Those from rVV-F-primed mice contained a mixture of CD8+ and CD4+ T cells, whereas those specific to G, N, and P were mostly CD4+. In contrast, 22K-specific lines were mostly CD8+. F- and 22K-specific lines showed virus-specific CTL activity against H-2d targets, but the lines from rVV-G-, -N-, and -P-primed mice did not. The F-specific lines contained Th cells that released an excess of IL-2 and some IL-3 but little IL-4 or IL-5 (i.e., a "Th1" pattern). In contrast, the G-specific line released IL-3, IL-4, and IL-5 but little IL-2 (i.e., a "Th2" pattern). The 22K line contained IL-3-releasing T cells. Staining of T cell subsets for CD45RB varied in intensity in different lines, consistent with the cytokine secretion profiles of the Th cells that they contained. Because different RS virus proteins (given in the same form by the same route) prime for functionally different T cells, the ways in which individual proteins are processed and presented might be important in determining these patterns of immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8515055

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

Review 2.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

Review 3.  Why do viruses make infants wheeze?

Authors:  I M Balfour-Lynn
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

4.  Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus.

Authors:  Nicholas W Lukacs; Martin L Moore; Brian D Rudd; Aaron A Berlin; Robert D Collins; Sandra J Olson; Samuel B Ho; R Stokes Peebles
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 5.  Virus-induced immunopathology.

Authors:  B T Rouse
Journal:  Adv Virus Res       Date:  1996       Impact factor: 9.937

6.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

Authors:  G E Hancock; D J Speelman; K Heers; E Bortell; J Smith; C Cosco
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  Induction of intercellular adhesion molecule-1 in human nasal epithelial cells during respiratory syncytial virus infection.

Authors:  Z Matsuzaki; Y Okamoto; N Sarashina; E Ito; K Togawa; I Saito
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

Review 8.  Immunopathological mechanisms in respiratory syncytial virus disease.

Authors:  P J Openshaw
Journal:  Springer Semin Immunopathol       Date:  1995

9.  Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Authors:  Kazuhiro Kakimi; Masanori Isogawa; JoSan Chung; Alessandro Sette; Francis V Chisari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.